This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weitz, J. Articles by Brennan, M. F. Search for Related Content PubMed PubMed Citation Articles by Weitz, J. Articles by Brennan, M. F. Social Bookmarking                            What's this?

Localized Extremity Soft Tissue Sarcoma: Improved Knowledge With Unchanged Survival Over Time

Jürgen Weitz, Christina R. Antonescu, Murray F. Brennan

From the Departments of Surgery and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Murray F. Brennan, MD, FACS, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; email: brennanm{at}mskcc.org.

Purpose: The objective of this study was to define whether survival of patients with extremity soft tissue sarcoma (STS), stratified for known risk factors, has improved over the last 20 years.

Patients and Methods: From January 1982 to December 2001, 1,706 patients with primary and recurrent STS of the extremities were treated at our institution and were prospectively followed. From this cohort, we selected 1,261 patients who underwent complete macroscopic resection and had one of the following histopathologies: fibrosarcoma, liposarcoma, leiomyosarcoma, malignant fibrous histiocytoma, or synovial sarcoma. Median follow-up was 55 months. Patient, tumor, and treatment factors were analyzed as prognostic factors.

Results: The 5-year disease-specific actuarial survival was 79% (78% for patients treated from 1982 to 1986, 79% for patients treated from 1986 to 1991, 79% for patients treated from 1992 to 1996, and 85% for patients treated from 1997 to 2001; P = not significant). For high-risk patients (high-grade, > 10 cm, deep tumors; n = 247), 5-year disease-specific survival was 51% (50% for patients treated from 1982 to 1986, 45% for patients treated from 1986 to 1991, 52% for patients treated from 1992 to 1996, and 61% for patients treated from 1997 to 2001; P = not significant). Tumor depth, size, grade, microscopic margin status, patient age, presentation status (primary tumor versus local recurrence), location (proximal versus distal), and certain histopathologic subtypes were significant prognostic factors for disease-specific survival on multivariate analysis; however, time period of treatment was not.

Conclusion: Prognosis of patients with extremity STS, stratified for known risk factors, has not improved over the last 20 years, indicating that current therapy has reached the limits of efficacy.

Supported by grant no. CA47179 (M.F.B.) from the National Institutes of Health, Bethesda, MD.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. Penel, A. Italiano, N. Isambert, E. Bompas, G. Bousquet, F. Duffaud, and on behalf of the French Sarcoma Group (Groupe Sarc Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy Ann. Onc., October 30, 2009; (2009) mdp485v1. [Abstract] [Full Text] [PDF]

				S. M. Schuetze and S. Patel Should Patients with High-Risk Soft Tissue Sarcoma Receive Adjuvant Chemotherapy? Oncologist, October 1, 2009; 14(10): 1003 - 1012. [Abstract] [Full Text] [PDF]

				S. Salas, B. Bui, E. Stoeckle, P. Terrier, D. Ranchere-Vince, F. Collin, A. Leroux, L. Guillou, J. J. Michels, M. Trassard, et al. Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database Ann. Onc., June 1, 2009; 20(6): 1127 - 1135. [Abstract] [Full Text] [PDF]

				A. J.F. Lazar, P. Das, D. Tuvin, B. Korchin, Q. Zhu, Z. Jin, C. L. Warneke, P. S. Zhang, V. Hernandez, D. Lopez-Terrada, et al. Angiogenesis-Promoting Gene Patterns in Alveolar Soft Part Sarcoma Clin. Cancer Res., December 15, 2007; 13(24): 7314 - 7321. [Abstract] [Full Text] [PDF]

				P. W.T. Pisters Preoperative Chemotherapy and Split-Course Radiation Therapy for Patients With Localized Soft Tissue Sarcomas: Home Run, Base Hit, or Strike Out? J. Clin. Oncol., February 1, 2006; 24(4): 549 - 551. [Full Text] [PDF]

				A. Ferrari, M. Casanova, P. Collini, C. Meazza, R. Luksch, M. Massimino, G. Cefalo, M. Terenziani, F. Spreafico, S. Catania, et al. Adult-Type Soft Tissue Sarcomas in Pediatric-Age Patients: Experience at the Istituto Nazionale Tumori in Milan J. Clin. Oncol., June 20, 2005; 23(18): 4021 - 4030. [Abstract] [Full Text] [PDF]

				E. L. Spurrell, C. Fisher, J. M. Thomas, and I. R. Judson Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital Ann. Onc., March 1, 2005; 16(3): 437 - 444. [Abstract] [Full Text] [PDF]

				A. Gronchi, P.G. Casali, L. Mariani, R. Miceli, M. Fiore, S. Lo Vullo, R. Bertulli, P. Collini, L. Lozza, P. Olmi, et al. Status of Surgical Margins and Prognosis in Adult Soft Tissue Sarcomas of the Extremities: A Series of Patients Treated at a Single Institution J. Clin. Oncol., January 1, 2005; 23(1): 96 - 104. [Abstract] [Full Text] [PDF]